Xontogeny is an accelerator operating company founded to increase the success rate of early life‑sciences technologies by partnering with founding scientists and entrepreneurs and providing leadership, strategic guidance and operational support. The firm assembles a senior team of experienced drug‑development professionals to advance a select portfolio of product candidates and technologies across serious disease areas from preclinical through clinical proof‑of‑concept. Chris Garabedian founded Xontogeny in June 2016 and serves as Chairman and CEO, partnering with portfolio companies as an active mentor, Executive Chair, or board member. Xontogeny provides program management, strategic direction, and a lean infrastructure to de‑risk programs until they are ready for further development. The company is building its team of experts and leveraging a network of advisors and service providers to support portfolio ventures. Financially, Xontogeny announced the closing of a $15 million tranche of a planned $25 million Series A financing to support operations and early‑stage development.

Total raised

$15M

Funding rounds

1

Latest round

Series A

Latest activity

May 2017